Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital NHS Trust, Norwich, NR4 7UY, UK.
Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK.
Ann Surg Oncol. 2022 Feb;29(2):767-775. doi: 10.1245/s10434-021-10911-4. Epub 2021 Oct 26.
Coregistered SPECT/CT can improve accuracy of sentinel node biopsy (SNB) for staging melanoma. This benefit has implications for pathology services and surgical practice with increased diagnostic and surgical workload. The purpose of this study was to investigate the effectiveness of SPECT/CT imaging.
SNB data were collected over a 10-year period. Preoperative SLN mapping was performed by using planar lymphoscintigraphy (LSG) for all patients (n = 1522) and after October 2015, patients underwent a second co-registered SPECT/CT scan (n = 559). The patients were stratified according to the imaging protocol. The number of nodes and nodal basins were assessed. The reasons for cancellation also were assessed.
A total of 95% (1446/1522) of patients underwent a successful SNB procedure. Significantly more sentinel nodes were identified by the SPECT/CT protocol (3 vs. 2; p < 0.0001). More patients were cancelled in the SPECT/CT cohort (9.3% vs. 2.5%; p < 0.0001). Head & neck, lower limb, and AJCC IB primaries were significantly less likely to proceed to SNB. SPECT/CT identified significantly more positive SNBs (20.9% vs. 16.5%; p = 0.038). SPECT/CT imaging was associated with improved disease-free (hazard ratio [HR] = 0.74; 95% confidence interval [CI]: 0.54-1.0); p = 0.048) and disease-specific survival (HR = 0.48; 95% CI: 0.3-0.78; p = 0.003). Patients who did not proceed to SNB had a significantly increased nodal relapse rate (23.5% vs. 6.8%; HR = 3.4; 95% CI: 1.9-6.2; p < 0.0001) compared with those who underwent SNB.
This large cohort study confirms the increased accuracy of SPECT/CT for identifying SLN metastases, which would appear to have a significant therapeutic benefit, although an increased risk of cancellation of the SNB procedure on the day of surgery.
SPECT/CT 配准可提高黑色素瘤前哨淋巴结活检 (SNB) 的准确性。这一优势对病理服务和外科实践产生影响,增加了诊断和手术工作量。本研究旨在探讨 SPECT/CT 成像的有效性。
收集了 10 年间的 SNB 数据。所有患者(n=1522)均行术前 SLN 映射,使用平面淋巴闪烁显像术(LSG),2015 年 10 月后,患者行二次配准 SPECT/CT 扫描(n=559)。根据成像方案对患者进行分层,评估淋巴结和淋巴结区的数量,还评估了取消的原因。
95%(1446/1522)的患者成功进行了 SNB 手术。SPECT/CT 方案显著增加了前哨淋巴结的检出数(3 个 vs. 2 个;p<0.0001)。SPECT/CT 组的取消率更高(9.3% vs. 2.5%;p<0.0001)。头颈部、下肢和 AJCC IB 原发性肿瘤进行 SNB 的可能性显著降低。SPECT/CT 显著增加了阳性 SNB(20.9% vs. 16.5%;p=0.038)。SPECT/CT 成像与无病生存(风险比 [HR] = 0.74;95%置信区间 [CI]:0.54-1.0;p=0.048)和疾病特异性生存(HR = 0.48;95% CI:0.3-0.78;p=0.003)的改善相关。未进行 SNB 的患者淋巴结复发率显著升高(23.5% vs. 6.8%;HR=3.4;95% CI:1.9-6.2;p<0.0001),而接受 SNB 的患者则较低。
本大样本队列研究证实,SPECT/CT 提高了识别 SLN 转移的准确性,这似乎具有显著的治疗益处,尽管在手术当天取消 SNB 手术的风险增加。